恶性肿瘤放疗前后血清可溶性白细胞介素2受体含量变化的临床意义

Changes of serum soluble interleukin 2 receptor (sIL 2R) in the patients with malignant tumor before and after radiotherapy and its clinical significance

目的 探讨血清可溶性白细胞介素２ 受体（ｓ Ｉ Ｌ２ Ｒ）水平与恶性肿瘤患者的病期及疗效的关系。方法 采用双抗体夹心 Ｅ Ｌ Ｉ Ｓ Ａ 法检测１５９ 例恶性肿瘤患者放疗前后血清ｓ Ｉ Ｌ２ Ｒ 水平。结果 恶性肿瘤患者放疗前血清ｓ Ｉ Ｌ２ Ｒ 水平明显高于正常对照组（ Ｐ＜ ００５）；放疗后血清ｓ Ｉ Ｌ２ Ｒ 水平明显低于放疗前（ Ｐ ＜ ０００１）；晚期患者（Ⅲ＋ Ⅳ期）不论是放疗前或放疗后 ｓ Ｉ Ｌ２ Ｒ 水平均明显高于早期患者（Ⅰ＋ Ⅱ期）（ Ｐ ＜ ００５）；各类恶性肿瘤之间血清ｓ Ｉ Ｌ２ Ｒ 水平无显著性差异（ Ｐ ＞００５）。结论 ｓ Ｉ Ｌ２ Ｒ水平在各种恶性肿瘤中的表达无特异性；检测恶性肿瘤患者ｓ Ｉ Ｌ２ Ｒ 放疗前后水平，是对病情估计和治疗疗效评价的一项参考指标。

Objective To investigate the relationship between the levels of serum soluble interleukin 2 receptor (sIL 2R) and the stages and therapeutic results of cancer patients Methods Using the method sandwich ELISA,the levels of sIL 2R in 159 cancer patients were measured before and after radiotherapy Results The serum sIL 2R levels in cancer patients were significantly higher than those of health controls (P<0 05);The levels after radiotherapy were significantly lower than those before radiotherapy (P<0 001);The levels of the stage Ⅲ and Ⅳ patients despite before or after radiotherapy were remarkably higher than those of the stage Ⅰ and Ⅱ (P<0 05);The levels in different malignant neoplasia had no significant difference (P>0 05) Conclusion The serum sIL 2R levels in different malignant neoplasia show no specificity;The serum sIL 2R levels in cancer patients can be used as a reference marker in assessment of the stage and therapeutic results